Following on from information provided to NICE by the company in October 2019, the appraisal of Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1481 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 11 October 2019 | Suspended. Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer |
| 11 October 2019 | The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps |
For further information on our processes and methods, please see our CHTE processes and methods manual